Skip to main content
. 2019 Jan 15;11(1):98. doi: 10.3390/cancers11010098

Figure 1.

Figure 1

Sensitivity to cetuximab treatment. (a) Dose–response curves for RAS wild-type colorectal cancer (CRC) cell lines after cetuximab treatment (168 h). Two out of four CRC cell lines (i.e., SW48 and HT29) were considered as intrinsically resistant to cetuximab. Cetuximab-sensitive CRC cell lines (i.e., Lim1215 and CaCo2) were used to generate isogenic cell lines with acquired cetuximab resistance. (b) Dose–response curves for isogenic CRC cell lines with acquired cetuximab resistance (Lim1215-R and CaCo2-R) and cetuximab-sensitive (Lim1215-PBS and CaCo2-PBS) CRC cell lines. (c) Dose–response curves for the CRC cell lines with acquired cetuximab resistance after 6 weeks of culture in drug-free medium, followed by cetuximab treatment for 168 h. This graph represents two independent experiments executed in threefold.